Dr. Kurmi received his undergraduate degree from Tribhuwan University, Nepal and PhD in Public Health from the University of Aberdeen, UK. He completed his post-doctoral training at the University of Birmingham, UK, in the Institute of Occupational Medicine. He worked as a Senior Scientist in Respiratory Epidemiology at the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, the University of Oxford, UK. He worked as an Assistant Professor in Respiratory Epidemiology in the Division of Respirology, Department of Medicine, McMaster University, Hamilton, Canada. Currently, he is working as an Associate Professor in Epidemiology and Evidence-based Healthcare Research at Coventry University. He is the chair of the Respiratory Epidemiology Group (6.01) of the European Respiratory Society and the Fellows of the Royal Society of Public Health. He has worked in several large prospective cohorts across all geographical regions, including in biobank studies. His primary research expertise is Respiratory Epidemiology and Environmental Health Epidemiology, and he has been teaching observational research methods and problem-based learning to undergraduate and postgraduate students. He has set up a family cohort in two regions of Nepal to understand the major determinants of health, particularly lung health in children.
Research Associate Biology
Brookhaven National Laboratory
Upton, NY 11973-5000, USA
Education
PhD, Plant Molecular Biology from Mississippi State University, USA.
Additional Information
Dr. Sah born in Haripurwa Municipality, Sarlahi district Nepal. He did his undergraduate studies in BSc. In Applied Biotechnology at Lord Buddha Education Foundation, Maitidevi, Kathmandu. After completion of his undergraduate, he worked in the Biotechnology section at the Department of Plant Resources, Thapathali. Later, he moved to Punjab Agriculture University, Ludhiana, India to pursue a master’s in biotechnology. After his master’s, he worked two years as a Research Fellow at Punjab Agricultural University. After that, he moved to the United States to pursue PhD in Molecular Biology. He did postdoctoral training at The Pennsylvania State University. Now, He is working as a Research Associate Biology at Brookhaven National Laboratory, New York. Currently, he is working on enhancing the oil synthesis in the leaf and stem of Arabidopsis, sugarcane, and rice. He has worked on several projects in Abiotic Stress, Gene editing, ABA signaling in plants.
Dr. Pangeni was born and raised in Syangja, Nepal. He moved to Mumbai after high school to pursue his higher education. He returned to Nepal and worked in various schools and colleges as a teacher/lecturer and moved to the United Kingdom to pursue his Masters and Ph.D. Dr. Pangeni has received his post-doctoral training from Northwestern University and City of Hope National Medical Center in the USA. He received his research training in cancer epigenetics during his Ph.D. and postdoctoral fellowships. Currently, he works on Cancer Genetics/epigenetics and metastases, Cancer epidemiology,
Experimental therapeutics,
Disease diagnostics and drug discovery
Senior Research Scientist
Central Department of Microbiology – CDM, Tribhuvan University
Kirtipur Kathmandu – 44601, Nepal
Education
PhD, Molecular Biology and Immunology, Thammasat University, Thailand (2014)
Master of Science (M.Sc.), Medical Microbiology, Tribhuvan University, Nepal (2004)
Postdoctoral Research Fellow
QIMR Berghofer Medical Research Institute
Brisbane, QLD, Australia
Education
PhD, Centre for Personalised Cancer Medicine, School of Medicine, The University of Adelaide, Australia
B.Sc. in Biotechnology (Hons.), SANN International College, Purbanchal University, Nepal
Additional Information
Dr Reshma Shakya was born in Nepal. Dr Shakya graduated with a Bachelor of Science (Honors) majoring in Biotechnology from SANN International College, Purbanchal University, Nepal. She then moved to Australia and completed a PhD in Medicine degree from The University of Adelaide. Her PhD research was focused on understanding the impact of mutant p53 on tumour microenvironment and identifying potential biomarkers and therapeutic targets to treat mutant p53 expressing tumours. Dr Shakya then joined QIMR Berghofer Medical Research Institute, where she is studying the impact of tumour microenvironment and heterogeneity in clinical response and resistance to immunotherapy. She is also an ambassador for the DeNovo Software company based in California, United States. Dr Shakya provides scientific and technical knowledge about the company’s flagship project, a premier flow and image cytometry data analysis software. Dr Shakya’s research goal is to improve the clinical outcome of cancer patients by integrating histo-morphologic, genetic and immunologic features into the clinical trials of cancer immunotherapy and to improve the future design of personalised therapeutic strategies.
Specialization / Interest
Cancer immunology and Genetics
Immunotherapy
Molecular and Immunological Diagnostics
Clinical Trials and Clinical Research
Dr. Tara Sigdel is an associate professor of surgery at the University of California. He obtained his PhD in biochemistry from Miami University (OH) followed by postdoctoral training in biomarker discovery, immunology, and organ transplantation at Stanford University. Dr. Sigdel is actively involved in the identification of non-invasive biomarkers genes, peptides, proteins, and antibodies that monitor disease status after kidney transplantation. He has authored and co-authored more than 90 peer-reviewed scientific papers. Dr. Sigdel is also a founder, Board Member, and Director (Natural and Applied Sciences) of Nexus Institute of Research and Innovation (NIRI): a society established to promote quality research and innovation in Nepal and beyond. Dr. Sigdel is a founder member of the International Nepali Biomedical Society (INBS) which is established to promote networking and communication among Nepali who is in the field of biomedicine. Dr. Sigdel is passionate about communicating with the Nepali community in the US and in Nepal. He has been running “Chautari” both in person and online where he collaborates with Dr. Toya Baral to speak with guests who have useful messages to the community. Because of his passion for training and mentoring young students in Nepal, he is leading the collaboration between NIRI and Lokopakar to mentor public high school students in different districts of Nepal.
Team Lead – Immuno-Oncology
AstraZeneca Pharmaceuticals
Wilmington, DE 19850, USA
Education
Ph.D. University of Freiburg, Freiburg, Germany (2013)
M.Sc. Jawaharlal Nehru University, New Delhi, India (2009)
B.Sc. Manipal University, Manipal, India (2007)
Researcher – Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
Additional Information
Dr. Gautam was born and raised in Pokhara, Nepal. He moved to India to receive his B.Sc. from Manipal University, Manipal and M.Sc. in Biotechnology from Jawaharlal Nehru University, New Delhi. Subsequently, he moved to Europe to obtained PhD in Immunology from University of Freiburg, Germany. His research focus during his graduate study was immunology of innate immune cells and immunodeficiency developed due to genetic defects in transcription factors and metabolic enzymes. Successively, he joined the National Cancer Institute (NCI), National Institutes of Health (NIH), United States to conduct research in the field of T cell memory and immunotherapy, with a goal to develop novel immunotherapeutic regimens for metastatic cancer and viral infection. Since then he is involved in Immuno-Oncology research and is focused to generate next-generation immune cell therapy for terminal hematological malignancies and solid tumor indications.
Specialization / Interest
The innate and adaptive immune system, hematopoiesis, metabolism, T cell memory and adoptive T cell therapy, transfusion medicine, conventional and molecular diagnosis, translational sciences, a clinical trial involving novel cellular therapeutics for cancer/viral infection.